|
24. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month
randomized, placebo-controlled trial with a 6-month extension. The Galantamine
USA-1 Study Group. Neurology 2000;54(12):2261–8.
25. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine
in patients with mild to moderate Alzheimer’s disease: multicentre randomised
controlled trial. Galantamine International-1 Study Group. BMJ 2000;321(7274):1445–9.
26. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C,
and others. A 5-month, randomized, placebo-controlled trial of galantamine
in AD. The Galantamine USA-10 Study Group. Neurology 2000;54:2269–76.
27. Wilkinson D, Murray J. Galantamine: a randomized, double-blind, dose
comparison in patients with Alzheimer’s disease. Int J Geriatr Psychiatry
2001;16:852–7.
28. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of
a flexible galantamine dose in Alzheimer’s disease: a randomised, controlled
trial. J Neurol Neurosurg Psychiatry 2001;71:589–95.
29. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical
method for grading the cognitive state of patients for the clinician. J
Psychiatr Res 1975;12:189–98.
30. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease.
Am J Psychiatry 1984;141:1356–64.
31. Stern RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg
E, and others. A longitudinal study of Alzheimer’s disease: measurement,
rate, and predictors of cognitive deterioration. Am J Psychiatry 1994;151:390–6.
32. Han L, Cole M, Bellavance F, McCusker J, Primeau F. Tracking cognitive
decline in Alzheimer’s disease using the mini-mental state examination:
a meta-analysis. Int Psychogeriatr 2000;12:231–47.
33. Winblad B, Wimo A. Assessing the societal impact of acetylcholinesterase
inhibitor therapy. Alzheimer Dis Assoc Disord 1999;13(Suppl 2):S9–S19.
34. O’Brien BJ, Goeree R, Hux M, Iskedjian M, Blackhouse G, Gagnon M, and
others. Economic evaluation of donepezil for the treatment of Alzheimer’s
disease in Canada. J Am Geriatr Soc 1999;47:570–8.
35. Getsios D, Caro JJ, Caro G, Ishak, K. Assessment of health economics
in Alzheimer’s disease (AHEAD): galantamine treatment in Canada. Neurology
2001;57:972–8.
36. Giacobini E. Do cholinesterase inhibitors have disease modifying effects
in Alzheimer’s disease? CNS Drugs 2001;15:80–91.
37. Borroni B, Colciagli F, Pastorino L, Pettenati C, Cottini E, Rozzini
L, and others. Amyloid precursor protein in platelets of patients with
Alzheimer disease. Arch Neurol 2001;58:442–6.
38. Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil
HCL and cimetidine: assessment of pharmacokinetic changes following single
and multiple doses. Br J Clin Pharmacol 1998;46(Suppl 1):25–9.
39. Tiseo PJ, Perdoma CA, Friedhoff LT. Concurrent administration of donepezil
HCL and lectoconazole: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998;46(Suppl 1):30–4.
40. Tiseo PJ, Foley K, Friedhoff LT. Concurrent administration of donepezil
HCL and theophylline: assessment of pharmacokinetic changes following multiple-dose
administration in healthy volunteers. Br J Clin Pharmacol 1998;46(Suppl
1):35–9.
41. Tiseo PJ, Perdoma CA, Friedhoff LT. Concurrent administration of donepezil
HCL and digoxin: assessment of pharmacokinetic changes. Br J Clin Pharmacol
1998;46(Suppl 1):40–4.
42. Tiseo PJ, Foley K, Friedhoff LT. The effect of multiple doses of donepezil
HCL on the pharmacokinetic and pharmacodynamic profile of warfarin. Br
J Clin Pharmacol 1998;46(Suppl 1):45–50.
43. Grossberg GT, Shahelin HB, Messina JC, Anand R, Veach J. Lack of adverse
pharmacodynamic drug interactions with rivastigmine and twenty-two classes
of medications. Int J Geriatr Psychiatry 2000;15:242–7.
44. Compendium of Pharmaceuticals and Specialties 2002: The Canadian Drug
Reference for Health Professionals. Product Monograph.
45. Bullock R, Connolly C. Switching cholinesterase inhibitor therapy in
Alzheimer’s disease donepezil to rivastigmine, is it worth it? Int J Geriatr
Psychiatry 2002;17:288–9.
46. Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, and others.
Cholinergic markers in elderly patients with early signs of Alzheimer disease.
JAMA 1999;281:1401–6.
47. McKeith IG, Del Ser T, Spano P, Emre M, Wesnes L, Anand R, and others.
Efficacy of rivastigmine in dementia with Lewy bodies: a randomised double
blind placebo controlled international study. Lancet 2000;356:2031–6.
48. Lanctôt KL, Herrmann N. Donepezil for behavioral disorders associated
with Lewy Bodies: a case series. Int J Geriatr Psychiatry 2000;15:338–45.
49. Maclean LE, Collins CC, Byrne EJ. Dementia with Lewy bodies treated
with rivastigmine: effects on cognition, neuropsychiatric symptoms and
sleep. Int Psychogeriatr 2001;13:277–88.
50. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju
CRV. Efficacy of galantamine in probable vascular dementia and Alzheimer’s
disease combined with cerebrovascular disease: a randomised trial. Lancet
2002;359.
51. Litvan I. Therapy and management of frontal lobe dementia patients.
Neurology 2001;56(Suppl 4):S41–S45.
52. Litvan I, Phipps M, Pharr VL, Hallett M, Grafman J, Salazar A. Randomized
placebo-controlled trial of donepezil in patients with progressive supranuclear
palsy. Neurology 2001;57:467–73.
53. Henderson VW. The epidemiology of estrogen replacement therapy and
Alzheimer’s disease. Neurology 1997;48(Suppl 7):527–35.
54. Sherwin BB. Estrogen effects on cognition in menopausal women. Neurology
1977;48(Suppl 2):S21–S26.
55. Birge SJ. The role of estrogen in the treatment of Alzheimer’s disease.
Neurology 1997;48(Suppl 7):S36–S41.
56. Taber KH, Murphy DD, Blurton-Jones MM, Hurley RA. An update on estrogen:
higher cognitive function, receptor mapping, neurotrophic effects. J Neuropsychiatry
Clin Neurosci 2001;13:313–7.
57. Henderson VW, Paganini-Hill A, Miller BL, Elble RJ, Reyes PF, Shoupe
D, and others. Estrogen for Alzheimer’s disease in women: randomized, double-blind,
placebo-controlled trial. Neurology 2000;54:295–301.
58. Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, and others.
Estrogen replacement therapy for treatment of mild to moderate Alzheimer’s
disease: a randomized controlled trial. JAMA 2000;283:1007–15.
59. Marder K, Sano M. Estrogen to treat Alzheimer’s disease: too little,
too late? Neurology 2000;54:2035–7.
60. Yaffe K, Krueger K, Sarkar S, Grady D, Barrett-Connor E, Cox DA, and
others. Cognitive function in postmenopausal women treated with raloxifene.
N Engl J Med 2001;344:1207–13.
61. Asthana S, Baker LD, Craft S, Stanczyk FZ, Veith RC, Raskind MA, and
others. High-dose estradiol improves cognition for women with AD: results
of a randomized study. Neurology 2001;57:605–12.
62. Schneider LS, Farlow MR, Henderson VW, Pogoda JM. Effects of estrogen
replacement therapy on response to tacrine in patients with Alzheimer’s
disease. Neurology 1996;46:1580–4.
63. Cherrier MM, Asthana S, Plymate S, Baker L, Matsumoto AM, Peskind E,
and others. Testoterone supplementation improves spatial and verbal memory
in healthy older men. Neurology 2001;57:80–8.
64. Aisen PS. Inflammation and Alzheimer’s disease: mechanisms and therapeutic
strategies. Gerontology 1997;43:143–9.
65. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents
as possible protective factors for Alzheimer’s disease: a review of 17
epidemiologic studies. Neurology 1996;47:425–32.
66. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW,
and others. Clinical trial of indomethicin in Alzheimer’s disease. Neurology
1993;43:1609–11.
67. Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A double-blind,
placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease.
Neurology 1999;53:197–201.
68. Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, and
others. A randomized controlled trial of prednisone in Alzheimer’s disease:
Alzheimer’s Disease Cooperative Study. Neurology 2000;54:588–93.
69. Van Gool WA, Weinstein HC, Scheltens PK, Walstra GJ, Scheltens PK.
Effects of hydroxchloroquine on progression of dementia in early Alzheimer’s
disease: an 18-month randomised, double-blind, placebo-controlled study.
Lancet 2001;358:455–60.
70. Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T,
and others. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s
disease. N Engl J Med 2001;345:1515–21.
71. Marksbery WR. The role of oxadative stress in Alzheimer’s disease.
Arch Neurol 1999;56:1449–52.
72. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Gundman M, and
others. A controlled trial of selegiline, alpha-tocopherol, or both as
treatment for Alzheimer’s disease. NEJM 1997;336:1216–22.
73. Heart Protection Study Collaborative Group. MRC/BHF heart protection
study of antioxidant vitamin supplementation in 20,536 high-risk individuals:
a randomised placebo-controlled trial. Lancet 2002;360:7–22.
74. Adair JC, Knoefel JE, Morgan N. Controlled trial of N-acetylcysteine
for patients with probable Alzheimer’s disease. Neurology 2001;57:1515–7.
75. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Marksbery
WR. Brain infarction and the clinical expression of Alzheimer disease:
the nun study. JAMA 1997;277:813–7.
76. Guo Z, Fratiglioni L, Zhu L, Fastlom J, Winblad B, Viitanen M. Occurrence
and progression of dementia in a community population aged 75 years and
older: relationship of antihypertensive medication use. Arch Neurol 1999;56:991–6.
77. Forette F, Seux ML, Staessen JA, Th˙s L, Birkenhager WH, Babarskiene
MR, and others. Prevention of dementia in randomised double-blind placebo-controlled
systolic hypertension in Europe (Syst-Eur) trial. Lancet 1998;35:1347–51.
78. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and
the risk of dementia. Lancet 2000;356:1627–31.
79. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D’Agostino
RB, and others. Plasma homocysteine as a risk factor for dementia and Alzheimer’s
disease. NEJM 2002;346:476–83.
80. LeBars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF.
A placebo-controlled, double-blind randomized trial of an extract of ginkgo
biloba for dementia. JAMA 1997;278:1327–32.
81. Canadian Coordinating Office for Health Technology Assessment. Drug
treatments for Alzheimer’s disease: efficacy outcome measurements and cost-effectiveness;
2001.
82. Bae CY, Cho CY, Cho K, Oh BH, Choi KG, Lee HS, and others. A double-blind,
placebo-controlled multicenter study of cerebrolysin for Alzheimer’s disease.
J Am Geriatr Soc 2000;48:1566–71.
83. Reuther E, Husmann R, Kinzler E, Diabl E, Kingler D, Spatt J, and others.
A 28 week, double-blind, placebo-controlled study with cerebrolysin in
patients with mild to moderate Alzheimer’s disease. Int Clin Psychopharmacol
2001;16:253–63.
84. Winblad B, Poritis W. Memantine in severe dementia: results of the
M-BEST study (benefit and efficacy in severely demented patients during
treatment with memantine). Int J Geriatr Psychiatry 1999;14:135–46.
85. Schenk DB, Seubert P, Lieberburg I, Wallace J. b-Peptide immunization:
a possible new treatment for Alzheimer disease. Arch Neurol 2002;57:934–6.
86. Woolf SH, Grol R, Hutchinson A, Eccles M, Grunshaw J. Potential benefits,
limitations, and harms of clinical guidelines. BMJ 1999;318:527–30.
87. American Psychiatric Association. Practice guideline for the treatments
of patients with Alzheimer’s disease and other dementias of late life.
Am J Psychiatry 1997;154(Suppl):1–39.
88. Small GW, Rabins PV, Barry PP, Buckholtz NS, Dekosky ST, Ferris SH,
and others. Diagnosis and treatment of Alzheimer disease and related disorders:
Consensus statement of the American Association for Geriatric Psychiatry,
the Alzheimer’s Association, and the American Geriatrics Society. JAMA
1997;278:1363–71.
89. Patterson CJS, Gauthier S, Bergman H, Cohen CA, Feightner JW, Feldman
H, and others. The recognition, assessment and management of dementing
disorders: conclusions from the Canadian consensus conference on dementia.
CMAJ 1999;160 (Suppl 12):S1–S15.
90. Davis DA, Taylor-Vaisey A. Translating guidelines into practice: a
systematic review of theoretic concepts, practical experience and research
evidence in the adoption of clinical practice guidelines. CMAJ 1997;157:408–16.
91. Herrmann N. Pharmacotherapy for Alzheimer’s disease and other dementias.
Curr Opin Psychiatry 2002;15:403–9.
--------------------------------------------------------------------------------
Manuscript received and accepted July 2002.
1. Associate Professor, Department of Psychiatry; Head, Division of Geriatric
Psychiatry, Faculty of Medicine, University of Toronto Sunnybrook and Women’s
College Health Sciences Centre, Toronto, Ontario.
Address for correspondence: Dr N Herrmann, Faculty of Medicine, University
of Toronto, Sunnybrook & Women’s College Health Sciences Centre, 2075 Bayview
Avenue, Toronto, ON M4N 3M5
e-mail: nathan.herrmann@swchsc.on.ca
1 | 2 | 3 | 4 | 5
|
